For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| rhDNase I | rhDNase I 0.1% eye drops 4 times a day for 8 weeks rhDNase I: rhDNase I, 0.1% eye drops 4 times a day for 8 weeks | 0 | None | 0 | 29 | 17 | 29 | View |
| Vehicle | Drug vehicle eye drops 4 times a day for 8 weeks Vehicle: Drug vehicle 4 times a day for 8 weeks | 0 | None | 0 | 29 | 10 | 29 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Ocular discomfort | NON_SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Burning sensation | NON_SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Pain | NON_SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Blurring of vision | NON_SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Light sensitivity | NON_SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Dryness | NON_SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Redness | NON_SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Foreign body sensation | NON_SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Itching | NON_SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |